Q Biomed (QBIO) Stock Price, News & Analysis

Company Overview

Q Biomed Inc. is a biomedical development and commercialization company focused on acquiring, licensing and advancing healthcare technologies intended to address unmet medical needs. Rather than operating primarily as a traditional research-based pharmaceutical company, Q Biomed has historically pursued partnerships and strategic rights to drug candidates, medical technologies and other biomedical assets.

The company’s portfolio has included development programs in areas such as oncology, ophthalmology and neurological or developmental disorders. Q Biomed has also worked with external researchers, technology owners and commercial partners to support regulatory development, clinical evaluation and potential commercialization of its products. The specific composition and status of its portfolio may change as programs are licensed, expanded or discontinued.

Q Biomed has been associated with the development of products including QBM-001, an investigational treatment program targeting communication-related challenges in children with nonverbal autism, as well as other biomedical technologies obtained through licensing or acquisition arrangements. Publicly available information about the company’s current operations, leadership structure and geographic reach is limited, so investors should consult the company’s latest filings and disclosures for the most up-to-date details.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: N/A
• Average Volume: N/A
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Company Calendar

• Last Earnings: 7/14/2021
• Today: 9/29/2026
• Fiscal Year End: 11/30/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Healthcare Providers & Services
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:QBIO
• Previous Symbol: NASDAQ:QBIO
• CIK: 1596062
• Web: www.qbiomed.com
• Phone: (646) 889-2226
• Fax: N/A
• Employees: 3
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A